3-methyl-4-phenyl-1-(pyrimidin-2-yl)-1H-pyrazol-5-ol | 1068515-49-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 3-methyl-4-phenyl-1-(pyrimidin-2-yl)-1H-pyrazol-5-ol
• CAS: 1068515-49-0
• 化学式: C₁₄H₁₂N₄O
• 分子量: 252.275
• InChiKey: KUYVLBFMTIWSSC-UHFFFAOYSA-N

物化性质

• 沸点：
  483.3±47.0 °C(Predicted)
• 密度：
  1.30±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.34
• 重原子数：
  19.0
• 可旋转键数：
  2.0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  63.83
• 氢给体数：
  1.0
• 氢受体数：
  5.0

反应信息

• 作为产物：
  描述：

  溴苯 在 potassium phosphate 、 palladium diacetate 、 溶剂黄146 、 2-二-叔丁基磷-2'-甲基联苯 作用下， 以 甲苯 为溶剂， 反应 16.0h， 生成 3-methyl-4-phenyl-1-(pyrimidin-2-yl)-1H-pyrazol-5-ol
  参考文献：
  名称：

  Synthesis and biological evaluation of substituted pyrazoles as blockers of divalent metal transporter 1 (DMT1)

  摘要：

  Three distinct series of substituted pyrazole blockers of divalent metal transporter 1 (DMT1) were elaborated from the high-throughput screening pyrazolone hit 1. Preliminary hit-to-lead efforts revealed a preference for electron-withdrawing substituents in the 4-amido-5-hydroxypyrazole series 6a-l. In turn, this preference was more pronounced in a series of 4-aryl-5-hydroxypyrazoles 8a-j. The representative analogs 6f and 12f were found to be efficacious in a rodent model of acute iron hyperabsorption. These three series represent promising starting points for lead optimization efforts aimed at the discovery of DMT1 blockers as iron overload therapeutics. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.11.069

文献信息

• [EN] PYRAZOLE AND PYRROLE COMPOUNDS USEFUL IN TREATING IRON DISORDERS<br/>[FR] COMPOSÉS À BASE DE PYRAZOLE ET DE PYRROLE UTILES DANS LE TRAITEMENT DE TROUBLES DU MÉTABOLISME DU FER
  申请人：XENON PHARMACEUTICALS INC

  公开号：WO2008121861A2

  公开（公告）日：2008-10-09

  [EN] This invention is directed to pyrazole and pyrrole compounds, for example, compounds of formula (I): wherein R¹, R², R³ and R⁴ are as defined herein, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment of iron disorders. This invention is also directed to pharmaceutical compositions comprising the compounds and methods of using the compounds to treat iron disorders.
  [FR] L'invention concerne des composés à base de pyrazole et de pyrrole, par exemples des composés de formule (I) où R¹, R², R³ et R⁴ sont tels que définis dans la description, tels que leurs stéréoisomères, énantiomères, tautomères ou leurs mélanges, ou sels pharmaceutiquement acceptables, leurs solvates ou promédicaments, destinés au traitement de troubles du métabolisme du fer. L'invention concerne également des compositions pharmaceutiques renfermant ces composés et des procédés d'utilisation de ces composés pour traiter les troubles du métabolisme du fer.
• [EN] COMBINATION THERAPY FOR TREATING IRON DISORDERS<br/>[FR] POLYTHÉRAPIE DESTINÉE AU TRAITEMENT DE TROUBLES DU FER
  申请人：XENON PHARMACEUTICALS INC

  公开号：WO2010005851A1

  公开（公告）日：2010-01-14

  This invention is directed to combination therapies to treat iron overload disorders utilizing inhibitors of divalent metal transporter-1 (DMT1 ), proton pump inhibitors (PPIs), calcium channel blockers and iron chelators.